The Front Room — a clinical regulatory commons
RSS
← Back to The Docket
JUL 7 2026
APPROVED · 84 DAYS AGO

Vera Therapeutics — atacicept $VERA

for IgA nephropathy

BLA · Priority Review

About

IgA nephropathy is a kidney disease in which the immune system inflames the tiny filtering units inside the kidney, and in aggressive cases it can also damage the liver, skin, and heart. Atacicept is a lab-made protein that binds and blocks two immune signals, BLyS and APRIL, that tell B cells to multiply and churn out antibodies. Because those antibodies are thought to drive the kidney inflammation, quieting B cells this way may slow the damage that pushes patients toward dialysis.

Pivotal trial

ORIGIN 3 Phase 3 active not recruiting NCT04716231

A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)

Source: ClinicalTrials.gov

Also in development